SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more
SciVision Biotech Inc - Asset Resilience Ratio
SciVision Biotech Inc (1786) has an Asset Resilience Ratio of 7.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how SciVision Biotech Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down SciVision Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$194.63 Million | 7.46% |
| Total Liquid Assets | NT$194.63 Million | 7.46% |
Asset Resilience Insights
- Limited Liquidity: SciVision Biotech Inc maintains only 7.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SciVision Biotech Inc Industry Peers by Asset Resilience Ratio
Compare SciVision Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for SciVision Biotech Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for SciVision Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.03% | NT$165.40 Million | NT$2.35 Billion | -6.54pp |
| 2023-12-31 | 13.56% | NT$292.95 Million | NT$2.16 Billion | +9.42pp |
| 2022-12-31 | 4.14% | NT$86.87 Million | NT$2.10 Billion | +2.51pp |
| 2021-12-31 | 1.63% | NT$36.92 Million | NT$2.26 Billion | +0.79pp |
| 2020-12-31 | 0.84% | NT$15.94 Million | NT$1.89 Billion | -4.38pp |
| 2019-12-31 | 5.23% | NT$97.29 Million | NT$1.86 Billion | +4.27pp |
| 2018-12-31 | 0.96% | NT$16.21 Million | NT$1.70 Billion | -0.09pp |
| 2017-12-31 | 1.05% | NT$16.37 Million | NT$1.56 Billion | -9.27pp |
| 2016-12-31 | 10.32% | NT$140.02 Million | NT$1.36 Billion | -11.64pp |
| 2015-12-31 | 21.96% | NT$235.55 Million | NT$1.07 Billion | -9.14pp |
| 2014-12-31 | 31.10% | NT$339.61 Million | NT$1.09 Billion | +13.56pp |
| 2013-12-31 | 17.54% | NT$198.03 Million | NT$1.13 Billion | -10.72pp |
| 2012-12-31 | 28.26% | NT$136.59 Million | NT$483.28 Million | -5.31pp |
| 2011-12-31 | 33.58% | NT$135.61 Million | NT$403.87 Million | -- |